Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells

M. Murata, M. Towatari, H. Kosugi, M. Tanimoto, R. Ueda, H. Saito, T. Naoe

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Histone deacetylases are promising targets for cancer treatment. Here we studied the in vitro effects of a potent histone deacetylase inhibitor, FK228 (formerly FR901228), on human leukemia/lymphoma cells and cell lines compared with normal hematopoietic cells. In a lymphoma cell line, Raji, a nanomolar concentration of FK228 induced G1 arrest and/or apoptotic cell death, depending on the concentration and exposure time. Growth of lymphoid cell lines including Raji (N=13) was inhibited by 50% (IC50) after 2-day treatment at concentrations of 0.83 to 1.87 ng/ml. Viability of clinical samples from patients with acute lymphoblastic leukemia was decreased by 50% at 0.78±0.46 ng/ml, whereas the IC50 values for normal mononuclear cells from peripheral blood and bone marrow were 2.3±0.96 and 7.8±1.0 ng/ml, respectively. The IC50 values for normal progenitor cells were 3.1, 4.4 and 7.8 ng/ml for BFU-E, CFU-GM and CFU-Mix, respectively. Expression levels of HDAC-1 and HDAC-3 proteins, which varied among cell lines, but were stable during the treatment with FK228, did not correlate with the sensitivity to FK288. This novel agent might be useful in the treatment of lymphoid malignancies, because the above concentrations are clinically achievable in vivo according to a recent clinical study.

Original languageEnglish
Pages (from-to)1154-1160
Number of pages7
JournalJapanese Journal of Cancer Research
Volume91
Issue number11
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Lymphocytes
Inhibitory Concentration 50
Cell Line
Granulocyte-Macrophage Progenitor Cells
Histone Deacetylases
Lymphoma
Reference Values
Erythroid Precursor Cells
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blood Cells
Neoplasms
Leukemia
Cell Death
Stem Cells
Bone Marrow
romidepsin
Growth

Keywords

  • Apoptosis
  • FK228
  • Histone deacetylase inhibitor
  • Leukemia
  • Lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murata, M., Towatari, M., Kosugi, H., Tanimoto, M., Ueda, R., Saito, H., & Naoe, T. (2000). Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Japanese Journal of Cancer Research, 91(11), 1154-1160.

Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. / Murata, M.; Towatari, M.; Kosugi, H.; Tanimoto, M.; Ueda, R.; Saito, H.; Naoe, T.

In: Japanese Journal of Cancer Research, Vol. 91, No. 11, 2000, p. 1154-1160.

Research output: Contribution to journalArticle

Murata, M, Towatari, M, Kosugi, H, Tanimoto, M, Ueda, R, Saito, H & Naoe, T 2000, 'Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells', Japanese Journal of Cancer Research, vol. 91, no. 11, pp. 1154-1160.
Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H et al. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Japanese Journal of Cancer Research. 2000;91(11):1154-1160.
Murata, M. ; Towatari, M. ; Kosugi, H. ; Tanimoto, M. ; Ueda, R. ; Saito, H. ; Naoe, T. / Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. In: Japanese Journal of Cancer Research. 2000 ; Vol. 91, No. 11. pp. 1154-1160.
@article{300bdec03611442cb156b8d8bbcfcc03,
title = "Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells",
abstract = "Histone deacetylases are promising targets for cancer treatment. Here we studied the in vitro effects of a potent histone deacetylase inhibitor, FK228 (formerly FR901228), on human leukemia/lymphoma cells and cell lines compared with normal hematopoietic cells. In a lymphoma cell line, Raji, a nanomolar concentration of FK228 induced G1 arrest and/or apoptotic cell death, depending on the concentration and exposure time. Growth of lymphoid cell lines including Raji (N=13) was inhibited by 50{\%} (IC50) after 2-day treatment at concentrations of 0.83 to 1.87 ng/ml. Viability of clinical samples from patients with acute lymphoblastic leukemia was decreased by 50{\%} at 0.78±0.46 ng/ml, whereas the IC50 values for normal mononuclear cells from peripheral blood and bone marrow were 2.3±0.96 and 7.8±1.0 ng/ml, respectively. The IC50 values for normal progenitor cells were 3.1, 4.4 and 7.8 ng/ml for BFU-E, CFU-GM and CFU-Mix, respectively. Expression levels of HDAC-1 and HDAC-3 proteins, which varied among cell lines, but were stable during the treatment with FK228, did not correlate with the sensitivity to FK288. This novel agent might be useful in the treatment of lymphoid malignancies, because the above concentrations are clinically achievable in vivo according to a recent clinical study.",
keywords = "Apoptosis, FK228, Histone deacetylase inhibitor, Leukemia, Lymphoma",
author = "M. Murata and M. Towatari and H. Kosugi and M. Tanimoto and R. Ueda and H. Saito and T. Naoe",
year = "2000",
language = "English",
volume = "91",
pages = "1154--1160",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells

AU - Murata, M.

AU - Towatari, M.

AU - Kosugi, H.

AU - Tanimoto, M.

AU - Ueda, R.

AU - Saito, H.

AU - Naoe, T.

PY - 2000

Y1 - 2000

N2 - Histone deacetylases are promising targets for cancer treatment. Here we studied the in vitro effects of a potent histone deacetylase inhibitor, FK228 (formerly FR901228), on human leukemia/lymphoma cells and cell lines compared with normal hematopoietic cells. In a lymphoma cell line, Raji, a nanomolar concentration of FK228 induced G1 arrest and/or apoptotic cell death, depending on the concentration and exposure time. Growth of lymphoid cell lines including Raji (N=13) was inhibited by 50% (IC50) after 2-day treatment at concentrations of 0.83 to 1.87 ng/ml. Viability of clinical samples from patients with acute lymphoblastic leukemia was decreased by 50% at 0.78±0.46 ng/ml, whereas the IC50 values for normal mononuclear cells from peripheral blood and bone marrow were 2.3±0.96 and 7.8±1.0 ng/ml, respectively. The IC50 values for normal progenitor cells were 3.1, 4.4 and 7.8 ng/ml for BFU-E, CFU-GM and CFU-Mix, respectively. Expression levels of HDAC-1 and HDAC-3 proteins, which varied among cell lines, but were stable during the treatment with FK228, did not correlate with the sensitivity to FK288. This novel agent might be useful in the treatment of lymphoid malignancies, because the above concentrations are clinically achievable in vivo according to a recent clinical study.

AB - Histone deacetylases are promising targets for cancer treatment. Here we studied the in vitro effects of a potent histone deacetylase inhibitor, FK228 (formerly FR901228), on human leukemia/lymphoma cells and cell lines compared with normal hematopoietic cells. In a lymphoma cell line, Raji, a nanomolar concentration of FK228 induced G1 arrest and/or apoptotic cell death, depending on the concentration and exposure time. Growth of lymphoid cell lines including Raji (N=13) was inhibited by 50% (IC50) after 2-day treatment at concentrations of 0.83 to 1.87 ng/ml. Viability of clinical samples from patients with acute lymphoblastic leukemia was decreased by 50% at 0.78±0.46 ng/ml, whereas the IC50 values for normal mononuclear cells from peripheral blood and bone marrow were 2.3±0.96 and 7.8±1.0 ng/ml, respectively. The IC50 values for normal progenitor cells were 3.1, 4.4 and 7.8 ng/ml for BFU-E, CFU-GM and CFU-Mix, respectively. Expression levels of HDAC-1 and HDAC-3 proteins, which varied among cell lines, but were stable during the treatment with FK228, did not correlate with the sensitivity to FK288. This novel agent might be useful in the treatment of lymphoid malignancies, because the above concentrations are clinically achievable in vivo according to a recent clinical study.

KW - Apoptosis

KW - FK228

KW - Histone deacetylase inhibitor

KW - Leukemia

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0033639025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033639025&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 1154

EP - 1160

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -